Michael Sean Merrill Covey, Chief Product Officer of Franklin Covey Co., filed a Form 4 on November 12, 2026, reporting two transactions in the company's common shares dated November 10 and November 12, 2026.
Director Sandra S. Wijnberg filed a statement of changes in beneficial ownership with the SEC on November 12, 2026, reporting the acquisition of 1,305 shares of Automatic Data Processing Inc. common stock on November 11, 2026.
Director David W. Kenny of Automatic Data Processing Inc filed a statement of changes in beneficial ownership on November 12, 2026, reporting an acquisition of common stock on November 11, 2026.
Director Robert Holmes Swan filed a Form 4 with the SEC on November 12, 2026, reporting the acquisition of shares of Automatic Data Processing Inc common stock on November 11, 2026.
Director Julianne Bruno filed an initial statement of beneficial ownership with the SEC on November 12, 2026, reporting 33,442 shares of common stock in InMed Pharmaceuticals Inc. received through a merger effective November 6, 2026.
Commercial Vehicle Group, Inc. President and CEO David Ruppel filed a Form 4 on November 12, 2026, disclosing the acquisition of a combined 810,238 shares of common stock on November 9, 2026, granted as material inducement awards in connection with his acceptance of employment.
Director Michelle Patricia Pernice filed an initial statement of beneficial ownership with the SEC on November 12, 2026, reporting 27,868 shares of common stock in InMed Pharmaceuticals Inc. (trading as NASDAQ:MTRI) received through a merger effective November 6, 2026.
Director Nancy McKinstry filed a Form 4 with the SEC on November 12, 2026, disclosing the acquisition of 1,224 shares of Automatic Data Processing Inc common stock on November 11, 2026.
Syndax Pharmaceuticals Inc Chief Financial Officer Aaron Ondrey filed a Form 4 on November 12, 2026, disclosing the acquisition of 270,000 stock options on November 9, 2026.
Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kiselak, and Peter Evan Harwin filed a joint Form 3 initial beneficial ownership statement with the SEC on November 12, 2026, reporting holdings in InMed Pharmaceuticals Inc. (NASDAQ:MTRI) arising from a merger effective November …